EMA approves WELIREG® (belzutifan) for advanced clear cell RCC that progressed following a PD(L)-1 inhibitor and at least two VEGF therapies February 25, 2025
US FDA grants Fast Track Designation to Cu-67 SAR-bisPSMA for the treatment of metastatic CRPC patients February 25, 2025
ASCO GU 2025: PADCEV + KEYTRUDA Show Long-Term Efficacy in 1L Treatment of Locally Advanced or Metastatic Urothelial Cancer February 19, 2025
IMFINZI perioperative regimen improved EFS and OS across MIBC patients regardless of cPR status in post-hoc exploratory analysis of NIAGARA Ph 3 trial February 19, 2025
Data from Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median DOR of ~4 Years in Patients Achieving CR with JELMYTO Published in The Journal of Urology February 19, 2025
ASCO GU 2025: Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX + Opdivo in Patients with Advanced Kidney Cancer Announced February 19, 2025
ASCO GU 2025: New Data reported for Casdatifan in Patients with Metastatic Kidney Cancer February 19, 2025
ASCO GU 2025: New data for darolutamide confirm safety and improved efficacy across subgroups of patients with mHSPC February 19, 2025
OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals February 4, 2025
New Real-World DOR Data for JELMYTO Reports 68% RFS at Three Years in Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC) January 28, 2025
NDA initiated with US FDA for TAR-200 for patients with BCG-unresponsive high-risk NMIBC January 21, 2025
Sasanlimab in Combination with BCG Improves EFS in Patients with BCG-Naïve, High-Risk NMIBC January 15, 2025
CAN-2409 Achieved Primary Endpoint in Ph 3 Prostate Cancer Trial, Showing Significantly Improved DFS December 18, 2024
Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of VHL Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced RCC December 18, 2024
Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive NMIBC December 10, 2024
Doses Selected for Ph 1b Expansion Trials Supported by Efficacy & Safety Profile Observed in Ph 1a Dose Escalation for JANX007 in metastatic CRPC December 10, 2024
